What is AURA's current stock price?

AURA (Aura Biosciences, Inc.) is currently trading at $7.60 with a market cap of $487.9M.

What sector is Aura Biosciences, Inc. in?

Aura Biosciences, Inc. (AURA) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is AURA a good stock to buy?

Analysts have a Buy consensus on AURA with a price target of $17.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

AURA Aura Biosciences, Inc.

Healthcare

$7.60-0.65%ClosedMarket Cap: $487.9M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

4.78

P/S

0.00

EV/EBITDA

-3.63

DCF Value

$0.67

FCF Yield

-18.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-78.1%

ROA

-81.6%

ROIC

-95.5%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-33.7M	$—
Q4 null	$0.00	$-25.6M	$—
FY null	$0.00	$-106.2M	$—
Q3 null	$0.00	$-26.1M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$17.00

Target (Median)

$17.00

Target Range

$17.00 - $17.00

1 Strong Buy5 Buy0 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-04-29

HC Wainwright & Co.Buy

2025-08-13

Trading Activity

Insider Trades

View All

Holles Natalie C.director, officer: See Remarks

SellTue May 19

Holles Natalie C.director, officer: See Remarks

SellTue May 19

Holles Natalie C.director, officer: See Remarks

SellTue May 19

Matrix Capital Management Company, LP10 percent owner

SellMon May 11

Holles Natalie C.

SellThu May 07

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.37

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

Peers

ALT

QSI